Literature DB >> 1127575

The role of the liver in the clearance of l-dope from plasma.

P T Mearrick, G G Graham, D N Wade.   

Abstract

The role of the liver in the plasma clearance of l-dopa in the rat was examined. Some published studies which ascribe an important role to the liver in l-dopa clearance are discussed and critically evaluated. Contrary evidence suggesting that the liver is not a significant site of l-dopa clearance in vivo is presented. The plasma concentration of l-dopa during intravenous infusion of the drug was not significantly reduced after a single passage through the liver. All of the data discussed are consistent with the conclusion that the liver plays a minor role in l-dopa clearance in vivo. It is suggested that the small intestine is the major site of metabolism of orally administered l-dopa.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1127575     DOI: 10.1007/bf01066592

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  14 in total

1.  Cerebral blood flow in the rat.

Authors:  L A SAPIRSTEIN; G E HANUSEK
Journal:  Am J Physiol       Date:  1958-05

2.  The behavior of intravenously injected particulate material; its rate of disappearance from the blood stream as a measure of liver blood flow.

Authors:  E L DOBSON; H B JONES
Journal:  Acta Med Scand Suppl       Date:  1952

3.  Decarboxylation of orally administered L-dopa in the human digestive tract.

Authors:  J Bergmark; A Carlsson; A K Granerus; R Jagenburg; T Magnusson; A Svanborg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

4.  Clearance concepts in pharmacokinetics.

Authors:  M Rowland; L Z Benet; G G Graham
Journal:  J Pharmacokinet Biopharm       Date:  1973-04

5.  Effect of L-aromatic amino acid decarboxylase inhibition on metabolism of dihydroxyphenylalanine by isolated perfused rat liver.

Authors:  G M Tyce; C A Owen
Journal:  Biochem Pharmacol       Date:  1972-11-15       Impact factor: 5.858

6.  Application of clearance concepts to some literature data on drug metabolism in the isolated perfused liver preparation and in vivo.

Authors:  M Rowland
Journal:  Eur J Pharmacol       Date:  1972-03       Impact factor: 4.432

7.  Kinetics of absorption and excretion of levodopa in dogs.

Authors:  C B Coutinho; H E Spiegel; S A Kaplan; M Yu; R P Christian; J J Carbone; J Symington; J A Cheripko; M Lewis; A Tonchen; T Crews
Journal:  J Pharm Sci       Date:  1971-07       Impact factor: 3.534

8.  L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro.

Authors:  L Rivera-Calimlim; J P Morgan; C A Dujovne; J R Bianchine; L Lasagna
Journal:  Biochem Pharmacol       Date:  1971-11       Impact factor: 5.858

9.  Semiautomated method for measurement of dopa in plasma.

Authors:  H E Spiegel; A E Tonchen
Journal:  Clin Chem       Date:  1970-09       Impact factor: 8.327

10.  Metabolism of thyroid hormones and some derivatives in isolated, perfused rat liver.

Authors:  E V Flock; C A Owen
Journal:  Am J Physiol       Date:  1965-11
View more
  5 in total

Review 1.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

2.  Systemic activity of orally administered L-dopa in the elderly Parkinson patient.

Authors:  M A Evans; E J Triggs; G A Broe; N Saines
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

3.  A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.

Authors:  S Grange; N H Holford; T W Guentert
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

4.  Intestinal absorption of levodopa in man.

Authors:  U Gundert-Remy; R Hildebrandt; A Stiehl; E Weber; G Zürcher; M Da Prada
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration.

Authors:  E Bredberg; H Lennernäs; L Paalzow
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.